ERIS Lifesciences Ltd logo

ERIS Lifesciences Ltd

ERIS NSE

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

AI Verdict: BUY Confidence: 7%

Eris Lifesciences trades at a PE of 30.6x with strong 3-year sales CAGR of 23% and TTM profit growth of 80%. With 90% analyst buy ratings and consistent ROE of 16-21% over the past decade, the stock offers a compelling growth story in chronic therapies, though valuation at 5.08x book and recent promoter selling warrant monitoring.

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹20,103 Cr
Volatility
Moderate
P/E Ratio
32.33
EBITDA
₹1,088 Cr
Return on Equity
16.85%
Debt to Equity
0.97
Book Value
₹281.64
EPS
₹27.95
52W High
₹1,885
52W Low
₹1,200

Technical Indicators

Key Insights

Weaknesses

3
  • Stock is trading at 5.21 times its book value
  • Promoter holding has decreased over last quarter: -0.93%
  • Tax rate seems low

Growth Rate

Revenue Growth
6.97% ↗
Net Income Growth
28.40% ↘
Cash Flow Change
119.13% ↗
ROE
-7.06% ↘
ROCE
11.27% ↗
EBITDA Margin (Avg.)
-2.00% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
BUY
Risk medium

Eris Lifesciences trades at a PE of 30.6x with strong 3-year sales CAGR of 23% and TTM profit growth of 80%. With 90% analyst buy ratings and consistent ROE of 16-21% over the past decade, the stock offers a compelling growth story in chronic therapies, though valuation at 5.08x book and recent promoter selling warrant monitoring.

Bull Case 8
  • Overwhelming analyst consensus with 90% buy ratings (9 out of 10 analysts recommend buy)
  • Exceptional TTM profit growth of 80% signals strong earnings momentum and operating leverage
  • Robust 3-year compounded sales CAGR of 23% demonstrates sustained revenue acceleration
  • Consistent ROE track record averaging 16-21% over 3, 5, and 10-year periods with last year at 19%
  • 5-year compounded sales growth of 21% reflects durable long-term business model in chronic therapies
  • 3-year stock CAGR of 29% indicates strong wealth creation for medium-term investors
  • Market cap of Rs 19,896 Cr provides adequate liquidity and institutional participation
  • 10-year compounded profit growth of 17% shows long-term earnings compounding ability
Bear Case 8
  • Stock trades at 5.08x price-to-book value, indicating expensive valuation relative to net assets
  • Promoter holding decreased by 0.93% in the last quarter, signaling potential insider confidence concerns
  • 1-year stock return of -11% shows recent underperformance despite strong fundamentals
  • PE ratio of 30.6x is elevated for a pharma company with only 8% TTM sales growth
  • TTM revenue growth has decelerated sharply to 8% from 3-year CAGR of 23%, raising slowdown concerns
  • Dividend yield of only 0.5% provides minimal income cushion during market downturns
  • Tax rate flagged as low, suggesting potential one-time benefits inflating reported profits
  • 5-year profit CAGR of only 12% lags behind sales CAGR of 21%, indicating historical margin pressure

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 14h ago
Headwinds 1
  • Exchange fines for board non-compliance May 28

    Eris Lifesciences was fined ₹4,24,800 each by BSE and NSE for non-compliance with board composition norms. The vacancy has since been filled as of March 14, 2026.

Positives 3
  • Strong FY27 revenue growth guidance Jun 24

    Eris targets 18-20% revenue growth in FY27 with stable EBITDA margins, aiming to grow at 1.3x CVM. In-sourcing of Sundae Pens from Q2 FY27 is expected to improve cost efficiency.

  • Top-5 anti-diabetes position, ₹3,318 Cr MAT Jun 23

    Eris reported MAT revenue of ₹3,318 Cr as of March 2026, holding 6% market share in anti-diabetes and 16% in insulins. Domestic Branded Formulations segment targets 37% EBITDA margin on a ₹2,778 Cr base.

  • Promoters hold 53.92% unencumbered stake May 28

    Promoters declared 7.47 crore shares fully free of encumbrance for FY26, signaling strong promoter confidence with no pledging.

Neutral 1
  • Routine NCD interest payment ₹109 Cr Jun 8

    Eris completed scheduled interest payments totaling ₹109.12 crore on two NCD tranches on June 8, 2026, reflecting ongoing debt servicing obligations.

TL;DR: Eris Lifesciences is executing well with clear FY27 guidance of 18-20% revenue growth, strong positioning in the high-growth diabetes segment, and healthy 37% EBITDA margin targets. The only headwind is a minor regulatory fine for board composition non-compliance, which has already been resolved. Promoter holding is fully unencumbered, and the Sundae Pens in-sourcing from Q2 FY27 could be an incremental margin lever. The trend is improving with visible earnings catalysts ahead.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
403
467
505
486
551
720
741
727
705
773
792
807
757
Expenses
284
297
324
311
402
470
477
477
453
496
504
526
484
Operating Profit
119
170
181
176
148
250
265
250
252
277
288
282
272
OPM %
30%
36%
36%
36%
27%
35%
36%
34%
36%
36%
36%
35%
36%
Other Income
1
1
3
4
15
2
5
4
8
4
3
-17
2
Interest
9
17
16
18
33
60
59
57
54
49
50
49
46
Depreciation
35
41
42
46
54
76
80
81
77
71
69
70
70
PBT
76
112
126
116
77
116
129
116
129
161
173
145
159
Tax %
19%
17%
3%
12%
-4%
22%
25%
25%
21%
22%
22%
25%
-75%
Net Profit
61
94
122
101
80
90
96
87
102
125
134
109
279
EPS in Rs
4.81
6.98
9.07
7.55
5.22
6.12
6.73
6.15
6.89
8.66
8.82
7.32
20.33
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
546
597
750
856
982
1,074
1,212
1,347
1,685
2,009
2,894
3,129
Expenses
427
425
480
533
637
702
781
858
1,146
1,332
1,876
2,009
Operating Profit
118
172
269
322
345
372
431
489
539
677
1,018
1,120
OPM %
22%
29%
36%
38%
35%
35%
36%
36%
32%
34%
35%
36%
Other Income
7
3
25
26
31
12
9
22
9
22
18
-9
Interest
0
0
1
11
23
2
2
4
26
85
231
193
Depreciation
16
20
23
26
36
50
43
65
117
183
315
280
PBT
109
154
270
312
317
331
394
442
405
431
489
639
Tax %
18%
13%
9%
6%
8%
11%
10%
8%
8%
8%
23%
-1%
Net Profit
89
135
247
295
291
297
355
406
374
397
375
648
EPS in Rs
6,489
9,714
17.95
21.39
21.15
21.84
26.16
29.88
28.1
28.82
25.84
44.72
Div. Payout %
0%
63%
0%
0%
0%
13%
21%
20%
26%
0%
28%
16%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.14
0.14
14
14
14
14
14
14
14
14
14
14
Reserves
266
299
553
848
1,137
1,283
1,563
1,895
2,182
2,573
2,841
3,889
Borrowings
1
0
1
377
176
0
7
84
877
2,781
2,478
2,359
Other Liabilities
91
98
124
170
175
205
202
233
337
1,366
1,412
1,104
Total Liabilities
357
397
692
1,408
1,502
1,502
1,785
2,226
3,410
6,734
6,744
7,366
Fixed Assets
72
71
232
771
761
875
854
918
2,568
4,319
5,306
5,188
CWIP
0
0
0
0
3
4
2
27
22
20
67
171
Investments
167
190
303
365
356
78
294
520
37
16
67
62
Other Assets
119
136
157
271
383
544
636
761
783
2,379
1,304
1,945
Total Assets
357
397
692
1,408
1,502
1,502
1,785
2,226
3,410
6,734
6,744
7,366
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
90
131
200
235
223
271
375
378
292
486
1,065
538
Investing
-92
-44
-184
-590
-5
123
-323
-320
-975
-1,828
-78
-369
Financing
0
-84
-24
363
-221
-335
-82
-45
688
1,380
-881
-314
Net Cash Flow
-2
4
-8
8
-3
60
-30
14
5
38
105
-145
Free Cash Flow
77
108
150
210
186
125
350
258
-550
357
910
241
CFO/OP
96
97
94
94
85
87
103
94
68
87
114
59
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
16
16
24
28
31
53
42
44
63
77
58
79
Inventory Days
223
178
195
178
196
148
145
166
136
182
171
200
Days Payable
142
92
134
247
200
213
157
166
129
210
170
151
Cash Conversion Cycle
97
102
84
-40
28
-12
30
44
70
48
59
129
Working Capital Days
15
9
23
-13
-17
59
64
75
50
-296
-49
-71
ROCE %
47%
53%
60%
34%
26%
25%
27%
25%
17%
11%
12%
14%

Shareholding Pattern

As of Mar 2026
Promoters 53.92%
DIIs 20.35%
Public 10.06%
Others 9.26%
FIIs 6.39%
Total 99.98%
  Jan 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
55.55%
54.13%
52.69%
52.68%
52.66%
52.66%
52.30%
52.29%
52.70%
52.86%
52.86%
54.91%
54.90%
54.90%
54.88%
54.87%
54.86%
54.85%
54.83%
54.85%
54.85%
53.92%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
13.20%
0.00%
14.27%
14.59%
8.01%
8.35%
8.43%
8.40%
7.21%
6.85%
6.39%
DIIs
10.52%
9.25%
9.66%
9.57%
9.99%
10.11%
10.36%
10.38%
9.94%
10.02%
10.28%
14.53%
13.86%
15.63%
16.23%
18.64%
18.06%
18.07%
18.17%
19.36%
20.32%
20.35%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
22.42%
23.28%
23.23%
23.29%
23.19%
23.14%
21.34%
21.27%
21.45%
21.66%
22.07%
15.47%
15.67%
14.24%
13.53%
10.51%
9.29%
9.16%
9.12%
9.12%
8.51%
10.06%
Others
11.51%
13.34%
14.42%
14.46%
14.16%
14.09%
16.01%
16.07%
15.90%
15.46%
14.79%
1.90%
15.57%
0.95%
0.77%
7.96%
9.43%
9.49%
9.47%
9.45%
9.48%
9.26%
No. of Shareholders
29,195
41,470
46,477
49,833
54,223
57,061
51,639
48,055
46,746
45,931
44,169
42,245
46,496
51,753
44,176
46,346
53,314
50,087
52,225
59,438
54,713
51,656

Documents

Frequently Asked Questions about ERIS Lifesciences Ltd

What does ERIS Lifesciences Ltd do?
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]
Where is ERIS Lifesciences Ltd (ERIS) listed?
ERIS Lifesciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: ERIS and BSE: 540596. You can view its live share price, financials, and ratios on Tapetide.
Which sector does ERIS Lifesciences Ltd belong to?
ERIS Lifesciences Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd has a market capitalisation of approximately ₹20102.57 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of ERIS Lifesciences Ltd?
The Price-to-Earnings (PE) ratio of ERIS Lifesciences Ltd is 32.33. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of ERIS Lifesciences Ltd?
Over the past 52 weeks, ERIS Lifesciences Ltd has traded between a low of ₹1,200 and a high of ₹1,885. This range helps investors understand the stock's price volatility and recent trading levels.
Does ERIS Lifesciences Ltd pay dividends?
Yes, ERIS Lifesciences Ltd has a dividend yield of 0.49%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd has a Return on Equity (ROE) of 16.85%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research ERIS Lifesciences Ltd on Tapetide?
On Tapetide, you can view ERIS Lifesciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Website eris.co.in
CEO Mr. Amit Indubhushan Bakshi
Employees 3,354
Listed 2017-06-29
Face Value ₹ 1
Issued Size 13,62,16,891

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List